|
Plümat Acquires Colpitt BV Plümat
is focussed on the design & manufacturing of form fill seal systems for
pharmaceutical solutions, whereas Colpitt is a well established specialist for
the supply of production equipment for disposable containers for blood,
intravenous and dialysis solutions and specialist in the field of RF technology
used for welding PVC, EVA and PU films.
The acquisition of Colpitt BV is part of Plümat’s core
strategy to widen the portfolio for high end pharmaceutical solution storage and
filling solutions. Given the quality level and reputation of both companies the
match is excellent and companies will keep supplying the existing range and will
in addition seek additional success by sharing know how and joining engineering
competences according to Sven-David Plate, share holder and managing director.
"Widen our range with Colpitt is the right decision for our
customers. Combining our know how will allow the combined companies to deliver
state of the art production technology and pharmaceutical expertise for
validation and customer support," said, share holder and managing director,
Sven-David Plate. "As both companies are known for supplying high-end medical
device and pharmaceutical production equipment, we will be able to maintain a
customer-centric focus on each individual automation project, and together the
Group becomes a one stop shop for a wide range of equipment”.
The acquisition further boosts Colpitt’s position as the
global leader in the blood bag and dialyses disposable bag production
technology. The combined organizations will offer a strong sales and service
network, a wider range of production technologies and also offers opportunities
in the storage solutions for cell growth and stem cell harvesting segments.
Arco Hamelink, the current general manager of Colpitt BV,
remains in position and will focus on operations in Zandvoort, The Netherlands.
The global headquarters remain in Espelkamp Germany, lead by Sven-David Plate
and Frank Lübeck.
Companies look forward to further establishing the
cooperation as we are uniting two industry leaders, both strongly focused on
people, know-how and customers. “Both organizations share a passion for
innovation and a commitment to developing and delivering customer quality and
satisfaction," said Frank Lübeck, share holder and managing director.
Financial reporting will be reported consolidated as per
second quarter of 2012, with the fiscal year ending December 31, 2011.
Foster Builds Medical Plastics Innovation Center
FOSTER Corporation, a PolyMedex Discovery Group company,
announces the opening of its Medical Plastics Innovation Center. The center
provides comprehensive development services of advanced polymer formulations
used in leading edge medical device. It offers polymer compounding, molding and
extrusion process evaluation, and material property testing.
Foster’s Medical Plastics Innovation Center is located within
the company’s Putnam, CT headquarters facility and includes a wide range of
equipment for comprehensive support of medical device development programs. At
the center of the facility is twin screw extrusion for blending and compounding
new medical polymer formulations, a core competency of Foster. The center also
includes downstream equipment for processing evaluation, including injection
molding and extrusion. The injection molding equipment is also suitable for
producing test samples for mechanical or environmental testing. The center is
equipped with an environmental oven for stability testing of polymers.
Foster has been at the forefront of producing custom
biomedical polymers for over 20 years, and is recognized as a leader in
radiopaque compounds, custom polymer blends, and custom colored polymers for
minimally invasive devices. The center supports new developments in these
materials for devices that push the envelope in size reduction and increased
performance. Nanocomposite reinforced polymers and melt filtered materials are
increasingly required to achieve the new standards of size and performance. The
center also supports the increasing demand for infection control materials with
anti-microbial additives, as well as tailored polymers for long term implants.
“As the market for medical devices evolves, materials of
construction become more critical,” says larry Acquarulo, CEO of Foster
Corporation. “For example, within the last 20 years the outside diameter of a
typical angiographic catheter has decreased by 70% while the working pressures
have increased well over 100%. This was made possible by improvements in polymer
technologies. Our Medical Plastics Innovation Center was created to provide
comprehensive development and evaluation of next generation materials for our
customers, from sample production to process and property evaluation.”
Foster Corporation supplies custom bio-medical polymers for
the medical device in dustry, including custom compounds for minimally invasive
devices, polymers blends for implants, and drug/polymer blends for combination
products. For more information, please visit
www.fostercomp.com |
